With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
Rs. 40 cr buyback, 200% dividend announced
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Subscribe To Our Newsletter & Stay Updated
